

% DR and DME per Region and per Country.

<b>Region/Country</b>	<b>% Diabetics diagnosed with DR</b>	<b>% Diabetics diagnosed with DME</b>
<b>Africa region</b>	<b>12</b>	<b>0</b>
South Africa	11	0
Uganda	12	0
<b>Eastern Mediterranean Region</b>	<b>18</b>	<b>11</b>
Algeria	19	13
Egypt	14	11
Lebanon	0	100
Saudi Arabia	14	9
United Arab Emirates	26	9
<b>European Region</b>	<b>20</b>	<b>9</b>
Bulgaria	50	20
Czech Republic	0	0
Denmark	15	8
Finland	37	17
France	16	15
Germany	21	14
Ireland	20	2
Italy	10	10
Netherlands	8	2
Norway	11	4
Poland	25	7
Portugal	29	11
Romania	27	13
Russia	31	25
Slovenia	22	5
Spain	16	7
Sweden	5	8
Turkey	12	3
United Kingdom	31	4
<b>Region of the Americas</b>	<b>19</b>	<b>6</b>
Argentina	13	7
Brazil	27	6
Canada	17	3
Chile	24	14

Colombia	28	12
Costa Rica	32	11
Mexico	11	3
Venezuela	11	0
<b>South East Asia Region</b>	<b>41</b>	<b>6</b>
Bangladesh	41	6
<b>Western Pacific Region</b>	<b>19</b>	<b>6</b>
Australia	22	3
China	24	13
Hong Kong	13	3
Japan	4	4
Malaysia	28	8
South Korea	10	16
<b>TOTAL</b>	<b>20</b>	<b>8</b>

## APPENDIX 2

Countries with national guidelines containing recommendations relating to screening of diabetic retinopathy

Country	Guideline title and reference
Australia	<a href="#">National Health and Medical Research Council (NHMRC) clinical guidelines. Diabetic retinopathy</a>
Canada	<a href="#">Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy.</a> Hooper P et al. <i>Can J Ophthalmol.</i> 2012 Apr;47(2 Suppl):S1-30, S31-54.
China	Chinese Ophthalmological Society. Retinopathy Working Group: diagnosis and treatment guideline of diabetic retinopathy <i>Chin J Ophthalmol</i> 2014; 50:851–86
Denmark	<a href="#">Evidence-based Danish guidelines for screening of diabetic retinopathy.</a> Grauslund J et al. <i>Acta Ophthalmol.</i> 2018;96:763-769 [6]
France	Recommendations of the ALFEDIAM (French Association for the Study of Diabetes and Metabolic Diseases) for the screening and surveillance of diabetic retinopathy. Massin P et al. <i>J Fr Ophtalmol.</i> 1997;20(4):302-10.
Germany	<a href="#">National guidelines for treatment of diabetic retinopathy: Second edition of the national guidelines for treatment of diabetic retinopathy</a> Ziemssen F et al. <i>Ophthalmic Epidemiol.</i> 2017;24(2):73-80.
Hong Kong	<a href="#">Primary Care Office, Department of Health. Hong Kong reference framework for diabetes care for adults in primary care settings</a>
India	<a href="#">VISION 2020: The Right To Sight India. Guidelines for diabetic eye care in India.</a>
Iran	<a href="#">Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population.</a> Rajavi Z et al. <i>J Ophthalmic Vis Res.</i> 2016 Oct-Dec;11(4):394-414.
Japan	<a href="#">Japanese Clinical Practice Guideline for Diabetes 2016.</a> Haneda M, et al. <i>J Diabetes Investig.</i> 2018; 9: 657–697.
Norway	<a href="#">The Diabetes guide-lines of the Norwegian College of General Practitioners</a> (Available at: <a href="http://www.helsedirektoratet.no/diabetes">http://www.helsedirektoratet.no/diabetes</a> )
New Zealand	<a href="#">New Zealand Ministry of Health. Diabetic retinal screening, grading, monitoring and referral guidance.2016</a>
Malaysia	<a href="#">Ministry of Health Malaysia. Screening of diabetic retinopathy.</a>

<b>Philippines</b>	<a href="#">Unite for Diabetes Philippines. Philippine practice guidelines for the diagnosis and management of diabetes: part 1- screening &amp; diagnosis.</a>
<b>Republic of Ireland</b>	<a href="#">Republic of Ireland Diabetic Eye Screening Service</a>
<b>Singapore</b>	<a href="#">Ministry of Health Singapore. Diabetes mellitus: MOH clinical practice guidelines 2014</a>

## APPENDIX 3

International guidelines for screening, treatment and management of diabetic eye disease

International Diabetes Federation and The Fred Hollows Foundation. Diabetes eye health: A guide for health care professionals ([www.idf.org/eyecare](http://www.idf.org/eyecare))[8]  
Available at: <https://www.idf.org/our-activities/care-prevention/eye-health/eye-health-guide.html>

2018 International Council of Ophthalmology Guidelines on Diabetic Eye Care – The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings[9]  
Available at: [https://www.aaojournal.org/article/S0161-6420\(17\)33523-6/fulltext](https://www.aaojournal.org/article/S0161-6420(17)33523-6/fulltext)

### References:

1. Access Economics Pty Limited. The global economic cost of visual impairment: Summary report. 2010.
2. International Diabetes Federation. IDF diabetes atlas 2017. In: Karuranga, S., da Rocha Fernandes, J., Huang, Y., Malanda, B, ed.2017.
3. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012;35(3):556-564. doi: 10.2337/dc11-1909 [doi].
4. *The diabetic retinopathy barometer report global findings*. Electronic Book; 2017.
5. Fenwick E, Rees G, Pesudovs K, et al. Social and emotional impact of diabetic retinopathy: A review. *Clin Exp Ophthalmol*. 2012;40(1):27-38. doi: 10.1111/j.1442-9071.2011.02599.x [doi].
6. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: Literature review. *Curr Med Res Opin*. 2010;26(7):1587-1597. doi: 10.1185/03007995.2010.482503 [doi].
7. Kaminsky TA, Mitchell PH, Thompson EA, Dudgeon BJ, Powell JM. Supports and barriers as experienced by individuals with vision loss from diabetes. *Disabil Rehabil*. 2014;36(6):487-496. doi: 10.3109/09638288.2013.800592 [doi].

8. Schmier JK, Covert DW, Matthews GP, Zakov ZN. Impact of visual impairment on service and device use by individuals with diabetic retinopathy. *Disabil Rehabil*. 2009;31(8):659-665. doi: 10.1080/09638280802239391 [doi].
9. Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: A population-based register study in sweden. *Diabetologia*. 2010;53(10):2147-2154. doi: 10.1007/s00125-010-1836-3 [doi].
10. Woung LC, Tsai CY, Chou HK, et al. Healthcare costs associated with progressive diabetic retinopathy among national health insurance enrollees in taiwan, 2000-2004. *BMC Health Serv Res*. 2010;10:136-6963-10-136. doi: 10.1186/1472-6963-10-136 [doi].
11. Devenney R, O'Neill S. The experience of diabetic retinopathy: A qualitative study. *Br J Health Psychol*. 2011;16(4):707-721. doi: 10.1111/j.2044-8287.2010.02008.x [doi].
12. Deloitte Access Economics. The economic impact of vision impairment and blindness in the republic of ireland. . 2011.
13. Schmitt-Koopmann I, Schwenkglenks M, Spinass GA, Szucs TD. Direct medical costs of type 2 diabetes and its complications in switzerland. *Eur J Public Health*. 2004;14(1):3-9.
14. Happich M, Reitberger U, Breitscheidel L, Ulbig M, Watkins J. The economic burden of diabetic retinopathy in germany in 2002. *Graefes Arch Clin Exp Ophthalmol*. 2008;246(1):151-159. doi: 10.1007/s00417-007-0573-x [doi].
15. Schmier JK, Covert DW, Lau EC, Matthews GP. Medicare expenditures associated with diabetes and diabetic retinopathy. *Retina*. 2009;29(2):199-206. doi: 10.1097/IAE.0b013e3181884f2d [doi].
16. Screening for diabetic retinopathy in europe – Progress since 2011, Satellite meeting to EASDec, manchester 2016. . May 2017.
17. Tapp RJ, Svoboda J, Fredericks B, Jackson AJ, Taylor HR. Retinal photography screening programs to prevent vision loss from diabetic retinopathy in rural and urban australia: A review. *Ophthalmic Epidemiol*. 2015;22(1):52-59. doi: 10.3109/09286586.2014.988875 [doi].
18. Chan CK, Gangwani RA, McGhee SM, Lian J, Wong DS. Cost-effectiveness of screening for intermediate age-related macular degeneration during diabetic retinopathy screening. *Ophthalmology*. 2015;122(11):2278-2285. doi: 10.1016/j.ophtha.2015.06.050 [doi].